AFM-Téléthon is sponsoring gene therapy research that will support a clinical trial for gamma-sarcoglycanopathy, limb-girdle muscular dystrophy. What is gamma-sarcoglycanopathy? LGMD2C affects less than 10 people per million and is characterized by progressive muscle...